TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-16
DOI
10.3389/fimmu.2019.01644
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
- (2019) Esma Saada-Bouzid et al. CURRENT OPINION IN ONCOLOGY
- Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
- (2018) Steven F. Gameiro et al. OncoImmunology
- Immune Checkpoint Inhibition in Head and Neck Cancer
- (2018) Martin David Forster et al. Frontiers in Oncology
- Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
- (2016) Julie George et al. CLINICAL CANCER RESEARCH
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment
- (2016) Sara I. Pai et al. ORAL ONCOLOGY
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
- (2016) Brooke E. Howitt et al. JAMA Oncology
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Extracellular vesicles: Exosomes, microvesicles, and friends
- (2013) Graça Raposo et al. JOURNAL OF CELL BIOLOGY
- Synthetic Oligodeoxynucleotides Containing Suppressive TTAGGG Motifs Inhibit AIM2 Inflammasome Activation
- (2013) J. J. Kaminski et al. JOURNAL OF IMMUNOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- B7 family checkpoint regulators in immune regulation and disease
- (2013) Sabrina Ceeraz et al. TRENDS IN IMMUNOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Differential Constitutive and Cytokine-Modulated Expression of Human Toll-like Receptors in Primary Neutrophils, Monocytes, and Macrophages
- (2012) D. Shane O'Mahony et al. International Journal of Medical Sciences
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual biological effects of the cytokines interleukin-10 and interferon-γ
- (2011) Cailin Moira Wilke et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients
- (2011) Paramita Baruah et al. IMMUNOBIOLOGY
- Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
- (2011) A. Kuznik et al. JOURNAL OF IMMUNOLOGY
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- PD-L1 expression on tolerogenic APCs is controlled by STAT-3
- (2010) Sabine J. Wölfle et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell Activity
- (2008) Irina V. Pinchuk et al. GASTROENTEROLOGY
- Attenuated Activation of Macrophage TLR9 by DNA from Virulent Mycobacteria
- (2008) Alexandra K. Kiemer et al. Journal of Innate Immunity
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now